Skip to content
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Neurology · Autoimmune Encephalitis

When Tests Are Negative: Seronegative Autoimmune Encephalitis

At a Glance

Seronegative autoimmune encephalitis means no known disease-related antibody was found, not that brain inflammation has been ruled out. Doctors combine the symptom pattern, MRI or spinal-fluid findings, and exclusion of infections or other causes to decide on treatment.

Hearing that you have an autoimmune disease of the brain can be overwhelming. Learning that the tests for that disease came back negative can feel like a contradiction [1]. You may feel a sense of “emotional whiplash”—caught between the relief of a negative test and the reality of the symptoms you are living with every day.

In many cases of autoimmune encephalitis (inflammation of the brain caused by the immune system), doctors cannot find a specific “marker” or antibody (a protein the immune system uses to target specific cells) in the blood or spinal fluid [2]. This is called seronegative or antibody-negative autoimmune encephalitis.

A negative test result does not mean the disease isn’t there; it means the standard tools used to find it didn’t see it [1]. This page explains why this happens and how doctors move forward when the labs are clear but the patient is not.

What “Seronegative” Actually Means

When a test is seronegative, it simply means the specific antibodies the lab was looking for were not detected [1]. A negative result can reflect assay performance, specimen choice, timing, low antibody concentration, prior immunotherapy, or the presence of a non-autoimmune illness entirely. There are several reasons why your tests might be negative even if your immune system is attacking your brain:

  • Undiscovered Antibodies: Scientists are discovering new antibodies every year. Your immune system may be using an antibody that hasn’t been identified by medical science yet [3].
  • Test Limitations: Most standard tests are cell-based assays, which look for a small “menu” of known targets. If your antibody isn’t on that specific menu, the test will be negative [4].
  • Tissue-Based Testing: Some specialized labs use tissue-based assays, which “screen” the immune system’s reaction against actual brain tissue. This can sometimes find evidence of an attack that standard tests miss, though it can also show nonspecific reactivity [4][5].
  • T-Cell Attacks: Sometimes, the immune system doesn’t use antibodies at all. Instead, researchers hypothesize it uses T-cells (white blood cells) to attack brain tissue directly. Because these aren’t antibodies, they will never show up on an antibody panel, though this remains a hypothesis for some cases [6].

The Supratentorial Region: The Seat of Thought

In this condition, the immune system often targets networks in the supratentorial region of the brain [7]. The “tentorium” is a flap of tissue that separates the top of the brain from the bottom. Supratentorial refers to everything above that flap.

Because this area includes the cerebral cortex and the limbic system, inflammation here often causes symptoms related to “higher” brain functions [8][9]:

  • Memory: Difficulty forming new memories or recalling recent events [10].
  • Emotion: Sudden anxiety, depression, or personality changes that seem out of character [9].
  • Thought: Confusion, “brain fog,” or difficulty processing information [7].
  • Seizures: Unusual electrical activity in the brain that may look like staring spells or physical shaking [11].

Recognizing a “Subacute” Onset

Doctors look for a specific timeline when diagnosing this condition. It is typically described as subacute, meaning the symptoms develop relatively quickly—usually over a period of weeks, but almost always reaching their peak within less than three months [2][12].

This timeline helps distinguish the disease from other conditions. For example, a stroke happens in minutes (acute), while a neurodegenerative disease like Alzheimer’s typically happens over years (chronic). The “weeks-to-months” window is a hallmark of an autoimmune process [13].

Diagnosis Based on Clinical Signs

Because antibody tests can be unreliable, doctors use a set of international standards called the Graus criteria to make a clinical diagnosis after appropriate testing and exclusion of alternatives [2].

Instead of waiting for a positive blood test, your medical team looks for a “syndrome”—a collection of signs that point to the diagnosis [1]:

  1. Clinical Symptoms: The specific memory, mood, or thought changes mentioned above.
  2. Supporting Evidence: This might include an MRI showing signs of swelling, new focal CNS findings, an unexplained seizure, or a lumbar puncture (spinal tap) showing signs of inflammation [14][15].
  3. Exclusion: Carefully ruling out other possible causes, such as infections or metabolic imbalances [13].

Moving Toward Treatment

The most important thing to know is that doctors do not have to wait for a positive antibody test to start treatment. If the clinical signs are strong enough and infections have been ruled out, they may begin empiric treatment [16].

Current guidelines suggest that earlier treatment is generally associated with better outcomes, to help protect the brain and improve the chances of a good recovery [16][17]. Treatment usually involves calming the immune system using medications like steroids or IVIG (intravenous immunoglobulin) [18]. While you will be monitored closely, a response to steroids is only one part of longitudinal clinical assessment and does not “confirm” the diagnosis by itself, as symptoms of other conditions can also fluctuate [1].

Common questions in this guide

What does seronegative autoimmune encephalitis mean?
It means that no known antibody linked to autoimmune encephalitis was detected in the blood or spinal fluid tested. It does not by itself rule out the condition, because current tests cover only some immune targets and results can be affected by timing, sample type, antibody level, or prior treatment.
Why can autoimmune encephalitis tests be negative?
Standard cell-based tests look for a limited list of known antibodies, and some antibodies may not yet be discovered. In some cases, the immune response may involve brain-tissue reactions or T cells rather than an antibody that the panel can detect.
What symptoms can supratentorial autoimmune encephalitis cause?
Inflammation above the tentorium can affect the cerebral cortex and limbic system. Patients may develop subacute changes in memory, mood, personality, thinking, or information processing, along with seizures such as staring spells or shaking.
How do doctors diagnose autoimmune encephalitis without a positive antibody test?
Doctors assess the pattern and speed of symptoms, often looking for memory, mood, thinking, or seizure changes that develop over weeks and peak within three months. They may use MRI, a spinal tap, and other neurologic findings while ruling out infections, metabolic problems, and other conditions; international criteria called the Graus criteria help organize this assessment.
Can treatment start if my autoimmune encephalitis antibody tests are negative?
Yes. If symptoms and supporting findings strongly suggest autoimmune encephalitis and infections have been ruled out, clinicians may start treatment before a disease-specific antibody is found. Common immune-calming treatments include steroids and IVIG, with the plan tailored to the patient.
How will doctors know whether treatment is helping without a positive antibody test?
They follow changes in memory, mood, thinking, seizures, examination findings, and relevant MRI or spinal-fluid results over time. Improvement after steroids can support the overall assessment, but it does not prove the diagnosis because other conditions can also fluctuate.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Could the behavioral or psychiatric changes we are seeing be 'autoimmune psychosis' rather than a primary mental health issue?
  2. 2.Was my antibody testing performed on both blood and spinal fluid, and did it include 'tissue-based' screening?
  3. 3.Is my brain inflammation located in the 'supratentorial' region, and how does that explain my specific symptoms?
  4. 4.What alternative diagnoses (like infections or other inflammatory conditions) have you ruled out so far?
  5. 5.Since we don't have a positive antibody test, how will we measure if the treatment is working?
  6. 6.Given the subacute onset of my symptoms, how soon should we start 'empiric' treatment?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    Diagnostic criteria for autoimmune encephalitis: utility and pitfalls for antibody-negative disease.

    Dalmau J, Graus F

    The Lancet. Neurology 2023; (22(6)):529-540 doi:10.1016/S1474-4422(23)00083-2.

    PMID: 37210100
  2. 2

    A clinical approach to diagnosis of autoimmune encephalitis.

    Graus F, Titulaer MJ, Balu R, et al.

    The Lancet. Neurology 2016; (15(4)):391-404.

    PMID: 26906964
  3. 3

    Testing for neural antibodies in autoimmune encephalitis: who, what, where, when, why, and how.

    Almweisheer S, Sangam K, Ismail O, Budhram A

    Therapeutic advances in neurological disorders 2026; (19()):17562864261429181 doi:10.1177/17562864261429181.

    PMID: 41836087
  4. 4

    Limitations of a Commercial Assay as Diagnostic Test of Autoimmune Encephalitis.

    Ruiz-García R, Muñoz-Sánchez G, Naranjo L, et al.

    Frontiers in immunology 2021; (12()):691536 doi:10.3389/fimmu.2021.691536.

    PMID: 34267758
  5. 5

    Improving the antibody-based evaluation of autoimmune encephalitis.

    McCracken L, Zhang J, Greene M, et al.

    Neurology(R) neuroimmunology & neuroinflammation 2017; (4(6)):e404 doi:10.1212/NXI.0000000000000404.

    PMID: 29075658
  6. 6

    CaV α2δ Autoimmune Encephalitis: A Novel Antibody and its Characteristics.

    Lee ST, Lee BJ, Bae JY, et al.

    Annals of neurology 2021; (89(4)):740-752 doi:10.1002/ana.26017.

    PMID: 33415786
  7. 7

    Autoimmune Encephalitis: Insights Into Immune-Mediated Central Nervous System Injury.

    Pai V, Kang H, Suthiphosuwan S, et al.

    Korean journal of radiology 2024; (25(9)):807-823 doi:10.3348/kjr.2023.1307.

    PMID: 39197826
  8. 8

    [Autoimmune encephalitis. A review].

    Collao-Parra JP, Romero-Urra C, Delgado-Derio C

    Revista medica de Chile 2018; (146(3)):351-361 doi:10.4067/s0034-98872018000300351.

    PMID: 29999106
  9. 9

    Evaluation of Cognitive Deficits and Structural Hippocampal Damage in Encephalitis With Leucine-Rich, Glioma-Inactivated 1 Antibodies.

    Finke C, Prüss H, Heine J, et al.

    JAMA neurology 2017; (74(1)):50-59 doi:10.1001/jamaneurol.2016.4226.

    PMID: 27893017
  10. 10

    Seronegative limbic encephalitis manifesting as subacute amnestic syndrome: a case report and review of the literature.

    Ismail II, Alnaser F, Al-Hashel JY

    Journal of medical case reports 2021; (15(1)):130 doi:10.1186/s13256-021-02742-4.

    PMID: 33757596
  11. 11

    Electroclinical features of seizures associated with autoimmune encephalitis.

    Steriade C, Moosa ANV, Hantus S, et al.

    Seizure 2018; (60()):198-204 doi:10.1016/j.seizure.2018.06.021.

    PMID: 30031297
  12. 12

    Autoimmune Encephalitis Misdiagnosis in Adults.

    Flanagan EP, Geschwind MD, Lopez-Chiriboga AS, et al.

    JAMA neurology 2023; (80(1)):30-39 doi:10.1001/jamaneurol.2022.4251.

    PMID: 36441519
  13. 13

    Mimics of Autoimmune Encephalitis: Validation of the 2016 Clinical Autoimmune Encephalitis Criteria.

    Van Steenhoven RW, de Vries JM, Bruijstens AL, et al.

    Neurology(R) neuroimmunology & neuroinflammation 2023; (10(6)) doi:10.1212/NXI.0000000000200148.

    PMID: 37582614
  14. 14

    The Laboratory Diagnosis of Autoimmune Encephalitis.

    Lee SK, Lee ST

    Journal of epilepsy research 2016; (6(2)):45-50 doi:10.14581/jer.16010.

    PMID: 28101474
  15. 15

    MR Imaging Findings in a Large Population of Autoimmune Encephalitis.

    Gillon S, Chan M, Chen J, et al.

    AJNR. American journal of neuroradiology 2023; (44(7)):799-806 doi:10.3174/ajnr.A7907.

    PMID: 37385678
  16. 16

    Brazilian consensus recommendations on the diagnosis and treatment of autoimmune encephalitis in the adult and pediatric populations.

    Dutra LA, Silva PVC, Ferreira JHF, et al.

    Arquivos de neuro-psiquiatria 2024; (82(7)):1-15 doi:10.1055/s-0044-1788586.

    PMID: 39089672
  17. 17

    Systematic Review and Meta-Analysis of the Clinical Features Associated With Seronegative Autoimmune Encephalitis.

    Di Cosmo L, Mulic-Al Bunni S, Goh Y, et al.

    Neurology(R) neuroimmunology & neuroinflammation 2026; (13(2)):e200540 doi:10.1212/NXI.0000000000200540.

    PMID: 41499723
  18. 18

    Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management.

    Abboud H, Probasco JC, Irani S, et al.

    Journal of neurology, neurosurgery, and psychiatry 2021; (92(7)):757-768 doi:10.1136/jnnp-2020-325300.

    PMID: 33649022

This page explains seronegative autoimmune encephalitis and negative antibody testing for informational purposes only and does not constitute medical advice. Your neurologist and care team should interpret your results and decide whether treatment is appropriate.

Get notified when new evidence is published on Non-specific autoimmune supratentorial encephalitis without characteristic antibodies.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.